Letter From the Editor
Letter From the Editor: Addressing the Racial Gap in Health Care
Advances in LLM
Is There a New Standard-of-Care Therapy for Advanced Hodgkin Lymphoma?
H&O What has been the traditional treatment for patients with advanced Hodgkin lymphoma? AH The traditional treatment for patients with stage III or IV Hodgkin lymphoma […]
In This Issue
From Recent Issues
Feature Article
Update on PARP Inhibitors for the Treatment of Ovarian Cancer
Abstract: Poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitors (PARPis) were first granted US Food and Drug Administration (FDA) approval for ovarian cancer. Trials have focused on high-grade serous […]
Feature Article
Targeting RAS in Gastrointestinal Malignancies
Abstract: Kirsten rat sarcoma virus (KRAS) is one of the prevalent oncogenic drivers in gastrointestinal (GI) cancers, including pancreatic ductal adenocarcinoma and colorectal cancer. The KRAS […]
Feature Article
Management of Oligoprogressive and Oligopersistent Disease in Advanced NSCLC
Abstract: The oligometastatic disease state is defined as an intermediate state between localized cancer and widespread systemic metastases. Oligoprogression is defined as a subgroup in which […]
Supplements
Modern Approaches in Neuroendocrine Tumors (NETs)
In the Clinic: Case Studies The following 2 patient cases highlight the clinical complexity of neuroendocrine tumors (NETs), and the widely different approaches in pancreatic NETs […]
Achieving Durable Response With the TRK Inhibitor Larotrectinib, and Possible Discontinuation of Therapy in Pediatric NTRK Gene Fusion–Positive Solid Tumors
In the Clinic: Case Studies In our clinic, the majority of pediatric patients presenting with neurotrophic tyrosine receptor kinase (NTRK) fusion–positive solid tumors are children diagnosed […]
Highlights in Renal Cell Carcinoma From the American Society of Clinical Oncology Genitourinary Cancers Symposium
A Review of Selected Presentations From the ASCO GU Symposium • February 13-15, 2025 • San Francisco, California Cabozantinib in Combination With Nivolumab and Ipilimumab in […]